IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

IDE397 Preclinical Efficacy and Pharmacodynamic Data Observed 100% Tumor SDMA Reduction at 30 mg/kg QD Dose in NSCLC MTAP PDX Model NSCLC SCC PDX Model (LXFE 2276) Vehicle, SDMA IHC 20x 92% TGI H-score 85 1000- 800- Vehicle IDE397 30mg/kg QD Mean Tumor Volume (mm³) ± S.E.M. 600- 400- 200- 0 10 10 IDEAYA Data 7 14 Study Day 21 LXFE 2276 T 28 - 29 IDE397 30 mg/kg QD, SDMA IHC 20x H-score 0 gsk IDEAVA BIOSCIENCES

View entire presentation